| Merged Markush Service (MMS) News
New DWPI/DWPX Display Formats Available for MMS Results
Questel recently added two new predefined formats to DWPI/DWPX specifically designed for MMS results. Both formats include the Compound Number (CN) field, but do not include the Derwent fragment and polymer indexing code fields, since these codes are often not needed for MMS results.
The first new format, TICN, which is free for Derwent subscribers, includes the Derwent Accession Number, the Derwent Enhanced Title, and the Compound Number field. It is useful for scanning titles and hit CNs for further investigation.
The second new format, MMSF, is similar to MAX and MAXC in that it contains the bibliographic patent family information and the Derwent abstract. We think MMSF will be useful for MMS, since MAX does not contain the CN field, and MAXC contains the other Derwent chemical indexing fields mentioned above, which can often result in lengthy record displays. As always, IMG can be added to any display command to add the patent front-page image to the display if available. Both LI and PRT commands can be used with predefined Questel displays.
The transcript below shows examples of TICN and MMSF using Imagination. Note that Hit CNs will appear with asterisks when using Imagination and in bold when using QWEB 3. Please consult the Questel Price List for pricing on these new formats for Derwent subscribers and nonsubscribers.
File DWPI
*mdarclist example3/cn
** SS 2: Results 48
Search statement 3
prt ticn 1-3
1/48 DWPI - (C) Thomson Reuters- image
AN - 2008-B39022 [09]
TI - New quinazoline derivative useful in treating or preventing
flaviviridae infection and Hepatitis C virus infection
CN - RA1QQM-K RA1QQM-M RA2H0J-K RA2H0J-M RA04O8-K RA04O8-M
***0402-75601-M*** ***0402-75601-N*** RA1Y9J-K RA1Y9J-M RAS14M-M
RAS14M-N RAS14N-M RAS14N-N RAS14O-M RAS14O-N RAS14P-M RAS14P-N
RAS14Q-M RAS14Q-N RAS14R-M RAS14R-N RAS14S-M RAS14S-N RAS14T-M
RAS14T-N RAS14U-M RAS14U-N RAS14V-M RAS14V-N RAS14W-M RAS14W-N
RAS14X-M RAS14X-N RAS14Y-M RAS14Y-N RAS14Z-M RAS14Z-N RAS150-M
RAS150-N RAS151-M RAS151-N RAS152-M RAS152-N RAS153-M RAS153-N
RAS154-M RAS154-N RAS155-M RAS155-N RAS156-M RAS156-N RAS157-M
RAS157-N RAS158-M RAS158-N RAS159-M RAS159-N RAS15A-M RAS15A-N
RAS15B-M RAS15B-N RAS15C-M RAS15C-N RAS15D-M RAS15D-N RAS15E-M
RAS15E-N RAS15F-M RAS15F-N RAS15G-M RAS15G-N RAS15H-M RAS15H-N
RAS15I-M RAS15I-N RAS15J-M RAS15J-N RAS15K-M RAS15K-N RAS15L-M
RAS15L-N RAS15M-M RAS15M-N
2/48 DWPI - (C) Thomson Reuters- image
AN - 2007-872057 [80]
TI - New substituted quinazolin-4-ylamino-phenyl compounds are B-Raf
inhibitors useful for the production of B-Raf inhibitory or
anti-cancer effect and to treat e.g. melanoma and cholangiocarcinomas
in a warm-blooded animal such as man
CN - RARN25-N RARN25-P RARN26-N RARN26-P RARN27-N RARN27-P RARN28-N
RARN28-P RARN29-N RARN29-P RARN2A-N RARN2A-P RARN2B-N RARN2B-P
RARN2C-N RARN2C-P RARN2D-N RARN2D-P RARN2E-N RARN2E-P 0401-47101-N
0401-47101-P 0401-47102-N 0401-47102-P ***0401-47103-N***
***0401-47103-P*** 0401-47104-N 0401-47104-P RARN2F-K RARN2F-S
RARN2G-K RARN2G-S
3/48 DWPI - (C) Thomson Reuters- image
AN - 2007-269849 [26]
TI - Treatment of tumor involves administration of human epithelial growth
factor receptor-2 dimerization inhibitor and epidermal growth factor
receptor inhibitor, to a human patient with a tumor expressing
epidermal growth factor receptor
CN - RA9WQM-K RA9WQM-M RAG2JQ-K RAG2JQ-M ***0345-35301-K***
***0345-35301-M*** RAPWWL-K RAPWWL-M RAPWWM-K RAPWWM-M RAPWWN-K
RAPWWN-M RAPWWO-K RAPWWO-M RAPWWP-K RAPWWP-M RAPWWQ-K RAPWWQ-M
RANNOH-K RANNOH-M RAPWWR-K RAPWWR-M RAPWWS-K RAPWWS-M RAPWWT-K
RAPWWT-M RAPWWU-K RAPWWU-M RAPWWV-K RAPWWV-M RAPWWW-K RAPWWW-M
RAPWWX-K RAPWWX-M RAPWWY-K RAPWWY-M RAPWWZ-K RAPWWZ-M RAPWX0-K
RAPWX0-M RAPWX1-K RAPWX1-M RA2OOA-K RA2OOA-M RAPWX2-K RAPWX2-M
RAPWX3-K RAPWX3-M RAPWX4-K RAPWX4-M RAPWX5-K RAPWX5-M RAPWX6-K
RAPWX6-M RADFQQ-K RADFQQ-M RAPWX7-K RAPWX7-M RAPWX8-K RAPWX8-M
RAPWX9-K RAPWX9-M RAPWXA-K RAPWXA-M RAPWXB-K RAPWXB-M RAPWXC-K
RAPWXC-M RAPWXD-K RAPWXD-M RAPWXE-K RAPWXE-M RAPWXF-K RAPWXF-M
RAPWXG-K RAPWXG-M RAPWY9-K RAPWY9-M RAPWXH-K RAPWXH-M RAPWXI-K
RAPWXI-M RAPWXJ-K RAPWXJ-M RAPWXK-K RAPWXK-M RAPWXL-K RAPWXL-M
RAPWXM-K RAPWXM-M RAPWXN-K RAPWXN-M RAPWXO-K RAPWXO-M RAPWXP-K
RAPWXP-M RAPWXQ-K RAPWXQ-M RAPWXR-K RAPWXR-M RAPWXS-K RAPWXS-M
RAPWXT-K RAPWXT-M RAPWXU-K RAPWXU-M RAPWXV-K RAPWXV-M RAPWXW-K
RAPWXW-M RAPWXX-K RAPWXX-M RAPWXY-K RAPWXY-M RAPWXZ-K RAPWXZ-M
RAPWY0-K RAPWY0-M RAPWY1-K RAPWY1-M RAPWY2-K RAPWY2-M RAPWY3-K
prt mmsf img 1
1/48 DWPI - (C) Thomson Reuters- image
CPIM Thomson Reuters
AN - 2008-B39022 [09]
XA - C2008-039217
TI - New quinazoline derivative useful in treating or preventing
flaviviridae infection and Hepatitis C virus infection
DC - B02 B04 C03
PA - (ARRO-) ARROW THERAPEUTICS LTD
IN - CHANA S; FRASER IJ; JENNENS L; MATHEWS N; PILKINGTON CJ; SPENCER KC;
THOMAS AJF; TIBERGHIEN N
NP - 1
NC - 116
PN - WO200780401 A1 20070719 DW2008-09 Eng 79p *
AP: 2007WO-GB00065 20070111
PR - 2006GB-0012116 20060119; 2006GB-0000510 20060111
IC - C07D-401/14; A61K-031/505; A61P-031/14; C07D-403/12; C07D-403/14;
C07D-405/14; C07D-409/14; C07D-401/00; A61P-031/00; C07D-403/00;
C07D-405/00; C07D-409/00
ICAA- C07D-401/14 [2006-01 A F I B - -]; A61K-031/505 [2006-01 A L I B - -];
A61P-031/14 [2006-01 A L I B - -]; C07D-403/12 [2006-01 A L I B - -];
C07D-403/14 [2006-01 A L I B - -]; C07D-405/14 [2006-01 A L I B - -];
C07D-409/14 [2006-01 A L I B - -]
ICCA- C07D-401/00 [2006 C F I B - -]; A61K-031/505 [2006 C L I B - -];
A61P-031/00 [2006 C L I B - -]; C07D-403/00 [2006 C L I B - -];
C07D-405/00 [2006 C L I B - -]; C07D-409/00 [2006 C L I B - -]
EC - C07D-401/14; C07D-403/12; C07D-403/14; C07D-405/14; C07D-409/14
DS - WO200780401
National States: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN
CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID
IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LV LY MA MD MG
MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG
SK SL SM SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
Regional States: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM
GR HU IE IS IT KE LS LT LU LV MC MW MZ NA NL OA PL PT RO SD SE SI SK
SL SZ TR TZ UG ZM ZW
AB - WO2007080401 A
NOVELTY: A quinazoline derivative or its salt is new.
- DESCRIPTION: A quinazoline derivative of formula (I) or its salt is
new. R1 = halogen, 1-6C alkyl, 1-4C haloalkyl, 1-6C alkoxy, 1-4C
haloalkoxy, A, A-Aa, A-Het-Aa, A-L-Aa, A-Het-L-Aa, A-L-Het-Aa,
A-Het-L-Het'-Aa or A-Het-L-Het'-La; R2 = H, halogen, 1-4C (halo)alkyl,
1-4C (halo)alkoxy, Het-Aa, Het-L-Aa, Het-L-Het'-Aa or Het-L-Het'-La;
R3 = H or 1-6C alkyl; R4 = halogen, 1-4C alkoxy or 1-4C (halo)alkyl;
R5 = H, 1-4C (halo)alkyl, 1-4C alkoxy, 1-4C aminoalkyl or
Het-L-Het'-La; R6 = H, 1-4C (halo)alkyl, 1-4C alkoxy, 1-4C aminoalkyl,
Het-L-Het'-La, CO-X or -L-X; X = ORa, NRaRb or 5-10 membered
heteroaryl or heterocyclyl group; Ra and Rb = H or 1-4C alkyl; n = 0,
1 or 2; A and Aa = phenyl, 5-10- membered heteroaryl, 5-10-membered
heterocyclyl or 3-6C carbocyclyl group (optionally fused to a further
phenyl, 5-10-membered heteroaryl, 5-10-membered heterocyclyl or 3-6C
carbocyclyl group); Het and Het' = O, S or NRa; L = 1-4C alkylene; La
= H, 1-4C alkyl, 1-4C haloalkyl, 1-4C hydroxyalkyl or 1-4C aminoalkyl.
The phenyl, heteroaryl, heterocyclyl and carbocyclyl groups in R1, R2
and R6 are optionally mono-tri-substituted by halogen, 1-4C
(halo)alkyl, 1-4C (halo)alkoxy, hydroxy, cyano, nitro or NRaRb.
INDEPENDENT CLAIMS are included for the following: (1) a product
containing the quinazoline derivative (I), or its salt and interferon
or an interferon derivative and/or ribavirin or a ribavirin derivative
for simultaneous, separate or sequential use in the treatment of the
human or animal body; and (2) use of an interferon or an interferon
derivative, in the manufacture of a medicament for use in treating or
preventing an HCV infection, by co-administration with a quinazoline
derivative of the formula (I) or its salt.
- ACTIVITY: Antiinflammatory; Hepatotropic; Virucide; Antipruritic;
Antidiarrheic. Huh-9B monolayers (liver cell line with persistent
bicistronic hepatitis C virus 1b genotype) were washed with phosphate
buffered saline is treated with trypsin. The cells were suspended in
growth media and counted. Plates were then incubated at 37degreesC in
5% carbon ioxide for 24 hours to obtain 90% confluent monolayers.
(6-Iodo-quinazolin-4-yl)-(4-(1,2,4)triazol-1-yl-phenyl)-amine (A) was
added in various dilution to the plate. The assay was run for 4 days
with ELISA development on the day 5. The IC50 value for the compound
(A) was calculated and was found to be less than 5 muM.
- MECHANISM OF ACTION: None given.
- USE: In the manufacture of a medicament for use in treating and
preventing a flaviviridae infection in human and animal e.g.
pestivirus infection (e.g. bovine viral diarrhea virus, classical
swine fever virus and border disease virus) and flavivirus infection
(e.g. yellow fever virus, dengue fever virus, Japanese encephalitis
virus, tick borne encephalitis virus, hepacivirus infection such as
hepatitis C virus) (all claimed).
- ADVANTAGE: The compound inhibits replication of the flaviviridae
viruses and effectively treats or prevents flaviviridae infection.
MC - CPI: B04-B03D B04-H05A B04-H05B B06-D06 B07-A02A B07-D13 B14-A02A7
B14-A02B9 B14-E02 C04-B03D C04-H05A C04-H05B C06-D06 C07-A02A C07-D13
C14-A02A7 C14-A02B9 C14-E02
CN - RA1QQM-K RA1QQM-M RA2H0J-K RA2H0J-M RA04O8-K RA04O8-M
***0402-75601-M*** ***0402-75601-N*** RA1Y9J-K RA1Y9J-M RAS14M-M
RAS14M-N RAS14N-M RAS14N-N RAS14O-M RAS14O-N RAS14P-M RAS14P-N
RAS14Q-M RAS14Q-N RAS14R-M RAS14R-N RAS14S-M RAS14S-N RAS14T-M
RAS14T-N RAS14U-M RAS14U-N RAS14V-M RAS14V-N RAS14W-M RAS14W-N
RAS14X-M RAS14X-N RAS14Y-M RAS14Y-N RAS14Z-M RAS14Z-N RAS150-M
RAS150-N RAS151-M RAS151-N RAS152-M RAS152-N RAS153-M RAS153-N
RAS154-M RAS154-N RAS155-M RAS155-N RAS156-M RAS156-N RAS157-M
RAS157-N RAS158-M RAS158-N RAS159-M RAS159-N RAS15A-M RAS15A-N
RAS15B-M RAS15B-N RAS15C-M RAS15C-N RAS15D-M RAS15D-N RAS15E-M
RAS15E-N RAS15F-M RAS15F-N RAS15G-M RAS15G-N RAS15H-M RAS15H-N
RAS15I-M RAS15I-N RAS15J-M RAS15J-N RAS15K-M RAS15K-N RAS15L-M
RAS15L-N RAS15M-M RAS15M-N
UP - 2008-09
UP4 - 2008-02
|
